Muscle Relaxant Drugs Market to Witness Growth because of Increasing Incidence of Skin Diseases

Today, the population of people aged 60 years or above is growing much faster than it was a few years back. As per the World Health Organization (WHO), the proportion of aged people will nearly double from 12% in 2015 to 22% in 2050. Owing to this, the medical settings need to be prepared for catering to the needs of this age group, since the geriatric population is more susceptible to diseases and therefore requires frequent and effective care. As a person grows older, their bodily functions start needing much more care. The physical body becomes weaker, which is why older people are also more prone to muscle spasms and body pain.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/muscle-relaxant-drugs-market/report-sample

Out of these, the demand for facial aesthetic relaxants was the highest in the past, which is basically because of the high safety and efficiency of these drugs. Different types of facial aesthetic relaxant drugs are dysport and Botox, between which, the demand for Botox was higher in the past. Other than this, the demand for skeletal muscle relaxants is also expected to rise in the near future. Antispastic and antispasmodic are two types of skeletal muscle relaxants. Antispastic agents are utilized for conditions such as multiple sclerosis and cerebral palsy and antispasmodic agents are used for the management of musculoskeletal conditions such as neck pain, tension headaches, and lower back pain.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=muscle-relaxant-drugs-market

The growing incidence of skin diseases is also resulting in the growing requirement for different muscle relaxant drugs. Factors such as exposure to ultraviolet radiation, excessive tobacco and alcohol consumption, and surging pollution lead to reduction in reduced skin elasticity and the skin becomes susceptible to sunburns. 

In addition to this, acne is the most common dermatological condition and affects a large number of people all across the globe. Attributed to these factors, people are increasingly making use of botulinum toxic-based muscle relaxant procedures for treating skin diseases.

Read More

Surging Geriatric Population Supporting the Wet Age-Related Macular Degeneration Sector Growth

The growing prevalence of age-related macular degeneration (AMD), lack of specific treatment availability, and increase in geriatric population are driving the growth of the wet age-related macular degeneration market. The market is projected to generate revenue worth $10.4 billion in 2024, witnessing a CAGR of 7.1% during the forecast period (2019–2024).  AMD is a disease in which blurred vision or blindness occurs due to damage to the retina macula. Wet AMD is a type of AMD characterized by the growth of abnormal blood vessels under the retina and macula.

On the basis of product, the wet age-related macular degeneration market is categorized into Eylea, Avastin, Lucentis, and others. Out of these, during the historical period (2014–2018), the Eylea category witnessed the fastest growth, and it is expected to keep growing during the forecast period at a CAGR of 10.0%. This is mainly attributed to the surging demand for this medication due to its low cost as well as high efficiency in the management of exudative or wet AMD.

Request to Get the Sample Pages at: 

The risk of developing AMD is directly proportional to age. With the number of people aged 60 years and above rising, the prevalence of AMD is also increasing. According to the World Population Prospects data published by the United Nations (UN), in 2017, there were about 962 million people in the age group 60 years or over across the globe, and the number is predicted to more than double by 2050, reaching 2.1 billion ultimately. Thus, it can be concluded that the geriatric population is rising faster than younger age groups.

Japan, Germany, Italy, and Portugal are among the nations with the largest population of elderly in the world. As older people are more prone to degenerative disorders, the increasing geriatric population in these countries is anticipated to contribute to the rising demand for drugs for wet AMD treatment, thus driving the wet age-related macular degeneration market during the forecast period.

Therefore, the surging geriatric population across the world is pushing the demand for drugs for treating wet AMD, resulting in the growth of the market.

Read More..

Read More

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, and Discovery Stage Insights

The global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different factors such as rising awareness for the cancer treatments, high demand for safe and effective medications, technologies advancements, and increasing prevalence of cancer.

Chronic lymphocytic leukemia is a type of gradually developing leukemia that affects the development of B lymphocytes (also known as B cells). On the other hand, B cells are specialized white blood cells, which produce immunoglobulins (also called antibodies) under normal conditions, and help to protect the human body against infections and diseases. In patients with chronic lymphocytic leukemia, lymphocytes undergo a malignant change and become leukemic cells.

Request to Get the Sample Pages at: 

Ono Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of chronic lymphocytic leukemia. Genentech is developing Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important role in suppressing the immune system triggered by the cancer. PD-L1 acts by reducing the proliferation of antigen-specific CD8+ T-cells and controlling the accumulation of foreign antigen-specific T-cells.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market

The chronic lymphocytic leukemia is more prevalent in North America, making the region to be the largest revenue contributor, globally. The U.S. contributed the largest revenue to the North American market in year 2016, and it is expected to remain the largest market across the globe, during the forecast period.

Some of the key players operating in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Novartis AG, and Johnson & Johnson.

Read More

Nuclear Medicine (Radiopharmaceuticals) Market by Overview, Growth Opportunities, Manufacturing Cost Structure Analysis, Outlook and Industry Insights Forecast to 2024

The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and cardiovascular diseases, and advances in nuclear medicine imaging procedures. High demand of nuclear medicines in emerging economies and potential radiopharmaceuticals in the pipeline create ample opportunities for the nuclear medicine/radiopharmaceuticals market to grow at a considerable rate in the coming years.

The advances in neurological applications and development of new products by the companies are supporting to address the demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging procedures are non-invasive and can be used for the treatment of several diseases, such as cancers, cardiovascular diseases, and neurological disorders.

Request to Get the Sample Pages at: 

The nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and region. On the basis of type, the nuclear medicine/radiopharmaceuticals market can be segmented as diagnostics and therapeutics. The diagnostics segment leads the nuclear medicine/radiopharmaceuticals market. The diagnostics segment can be further categorized into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT segment will be leading the nuclear medicine/radiopharmaceutical diagnostics market in the coming years due to its wider availability and less cost. The therapeutics segment can be further categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The beta emitters will be the leading segment in the global nuclear medicine/radiopharmaceutical therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market

Geographically, North America will be leading the global nuclear medicine/radiopharmaceuticals market in the coming years due to increasing prevalence of cancer, ready availability of radiopharmaceuticals, popularity of nuclear medicine among physicians, and technological advancements.

Asia-Pacific is the fastest growing region in the global nuclear medicine/radiopharmaceuticals market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, and rising awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan will be leading the nuclear medicine/radiopharmaceuticals market in Asia-Pacific region in the coming years.

Some of the major players operating in the global nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.

Read More

Global Endometrial Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

Global endometrial cancer therapeutics market is expected to witness significant growth as there are less number of approved drugs for treatment of endometrial cancer, leading to an increased opportunity for the drug manufacturers. High prevalence of cancer and rising demand for safe and effective medications can be attributed as the major drivers of this market. The regulatory bodies such as USFDA and EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.

Endometrial cancer is the malignancy that develops in the layers of the cells that forms endometrium, lining of uterus. The precise cause of endometrial cancer is still unknown but it is assumed that estrogen may be involved in developing endometrial cancer, as estrogen helps in the formation of the endometrial lining. Obesity, polycystic ovary syndrome, infrequent periods and history of endometrial polyps can increase the risk of endometrial cancer. Women with diabetes, high blood pressure or breast cancer are at a greater risk of having endometrial cancer. Abnormal vaginal bleeding, bleeding between periods or after menopause, lower abdominal cramps or clear vaginal discharge after menopause are some of the main symptoms of endometrial cancer.

Request to Get the Sample Pages at:

High prevalence and recurrence of endometrial cancer after treatment with chemotherapy are the major driving factors driving the endometrial cancer therapeutic market.  Growing prevalence of obesity in women aged 50 years or above is also contributing in the growth of the endometrial cancer therapeutics market globally. Apart from this, safety concerns after chemotherapy, hormone therapy and radiation therapy restrict the medications for the treatment of endometrial cancer.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=endometrial-cancer-treatment-market

Geographically, North America is expected to be the largest market for endometrial cancer therapeutics treatment, owing to the large number of research and development activities ad high healthcare expenditure. Europe is expected to hold the second largest share in the global market owing to growing product availability in the region.

Some of the key players operating in the global endometrial cancer therapeutics market are AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and R-Pharm-US LLC.

Read More

Biopharmaceuticals Market Size, Share, Development, Growth and Demand

View more on edocr

Read More

Breast Cancer Market Comprehensive Analysis of Market Trends, Technological Advancements, Company Profile and Growth Opportunities

Cancer is a disease characterized by uncontrolled growth of cell. There are about 100 different types of cancer and each is classified by the type of cell where it occurs and affects. Breast cancer is mostly prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma.

DCIS, also known as intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma originates in the lobules or milk glands of the breast. Invasive ductal carcinoma is the most common type of breast cancer. It starts in a milk duct of the breast, ruptures through the wall of the duct and grows into the fatty tissue of the breast. It spreads to other parts of body through bloodstream.

Request to Get the Sample Pages at:

North America accounts the largest global breast cancer market followed by Europe. The U.S., followed by Canada, is the largest market for breast cancer in North America. Key driving factor for this market is increasing prevalence of breast cancer in the region. Germany, France and the U.K. are some of the largest markets for breast cancer in Europe region. However, Asia-Pacific represents the fastest growing region in the global breast cancer market. This is due to improving healthcare infrastructure and increasing awareness among people about breast cancer. In developing countries, such as China and India, government has launched several programs and initiatives which increase awareness about the disease. It has led to significant rise in demand of breast cancer diagnostics and therapeutics for disease management. In addition, less stringent wages and availability of skilled labor attracts manufacturing companies to invest in developing countries. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=-breast-cancer-market

Increasing prevalence of the disease is a key driving factor for the global breast cancer market. Increasing awareness among people about the disease and rising number of geriatric women around the world are also supporting the growth of global breast cancer market. In addition, increased research in the field of oncology and development of biomarker has also fueled the growth of global breast cancer market. Increasing demand of advanced therapeutic drugs and extensive drug pipeline holds immense potential to the growth of the global breast cancer market.

Some of the major competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd.

Read More

Bile Duct Cancer Therapeutics Market Has Been Classified on the Basis of Disease Indication, Treatment Type and Geography

Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).

The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. 

Request to Get the Sample Pages at:

The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market

Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.

Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Read More

Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2023

The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants and designations. Thus, these regulatory bodies are amplifying the drug development process. 

Benign prostatic hyperplasia is also known as benign prostatic obstruction or benign prostatic hypertrophy, is a disease state in men, caused by prostate gland enlargement. Prostate develops in dual phase in entire life – the first phase occurs in initial phase of puberty, followed by the second phase that usually begins at the age of twenty-four and remains for most of a person’s life. Benign prostatic hyperplasia is a common problem in men aged above 50 years, and it occurs in the second phase of growth of prostate. However, the disease can also arise in men aged below 40 years, with the probabilities of its occurrence increasing with age.

Request to Get the Sample Pages at:

Aging population is the major factor on which the benign prostatic hyperplasia therapeutics market is mostly dependent. Asia-Pacific and European markets for benign prostatic hyperplasia therapeutics are likely to observe significant growth rates, during the forecast period, due to increase in aging population in these regions. The Latin American and North American markets for benign prostatic hyperplasia therapeutics are also projected to observe strong growth rates, during the forecast period.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-therapeutics-market

Some of the key players operating in the global benign prostatic hyperplasia therapeutics market include Sandoz, Inc., Sanofi Aventis, Labopharm, Inc., Pfizer, Inc., and Teva Pharmaceuticals, Inc.

Read More

Acute Myeloid Leukemia (AML) Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at:

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Acute Lymphoblastic Leukemia (ALL) Therapeutics Market Share Assessments for the Regional and Country Level Segments

The global acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth in the coming year since new drug formulations are proving to be the most effective treatment for cancer. An increasing awareness regarding cancer treatment, various technological advancements, high demand for safe and effective medications and high prevalence of cancer, are driving the growth of the global acute lymphoblastic leukemia therapeutics market. The regulatory bodies are also supporting the growth of the global market by providing funding, designations and grants to speed up the drug development process. 

The pipeline of acute lymphoblastic leukemia contains GRASPA (Erythrocytes Encapsulating L-asparaginase), a Phase I drug candidate of ERYtech Pharma, Inc. GRASPA is an encapsulated L-asparaginase product, using the company’s proprietary ERYCAPS platform technology for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA causes systemic degradation of asparagine and inhibits the growth and survival of cancer cells.

Download Report Sample Copy at:   

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids are showing good results for the treatment of acute lymphoblastic leukemia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-lymphoblastic-leukemia-therapeutics-market

Geographically, North America is expected to be the largest market for acute lymphoblastic leukemia, owing to a large number of research and development activities, high healthcare expenditure, and increasing prevalence of cancer. According to National Cancer Institute, estimated new cases of acute lymphoblastic leukemia were 6,590 and estimated deaths were 1,430 in 2016, in the U.S. The U.S. contributed the largest revenue to the North American market in 2016, and it is expected to remain the largest market, globally, during the forecast period.

Some of the key players operating in the global acute lymphoblastic leukemia treatment market are Spectrum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc., ERYtech Pharma, Pfizer, Inc., Amgen, and Takeda Pharmaceutical Company Limited.

Contact:

P&S Intelligence

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Gastrointestinal Over the Counter (OTC) Drugs Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The gastrointestinal over the counter drugs market is growing at a significant rate mainly due to increase in patient population. Strategic alliances are one the major trends that can be seen in the gastrointestinal over the counter drugs market and is supporting the market to grow at a more considerable rate.

Gastrointestinal diseases involve the gastrointestinal tract including stomach, esophagus, large intestine, small intestine, gallbladder, rectum, liver and pancreas. Over the counter (OTC) drugs are medications that are available without any prescription from the doctor. Over the counter drugs are chosen by regulatory agencies very carefully so as to ensure their efficacy and safety.

Request to Get the Sample Pages at: 

The gastrointestinal over the counter drugs can also be bought without any prescription of doctor. The gastrointestinal over the counter drugs are used for indications such as vomiting, gastro esophageal reflux disease (GERD), diarrhea, flatulence and constipation. The over the counter drugs are not compelled by regulatory guidelines, but they need to fulfill the drug monograph of a certain country.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=gastrointestinal-otc-drugs-market

In the U.S., the Food and Drug Administration regulates the manufacturing and sale of over the counter drugs. The Food and Drug Administration compels that all new drugs should obtain a new drug application (NDA) before it enters throughway, but the act excuse any drug which is recognized as effective and safe for the requirement. Some of the over the counter drugs approved in the U.S. are anti-microbial, sunscreens, anti fungal products, and internal and external analgesics. In the U.K., Medicines Regulations 2012 governs the medication. Medication in the country is categorized as a general sales list, prescription only medication and pharmacy medicines.

Some of the competitors in the gastrointestinal over the counter drugs market are Procter & Gamble, GlaxoSmithKline Pharmaceuticals Limited, Purdue Pharma L.P., Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Reckitt Benckiser Group plc, C.B. Fleet Company, Inc., Perrigo Company plc, Sanofi, OMEGA SA, Abbott Laboratories, and Nestle SA.

Read More

Anti-Obesity Drugs Market Analysis by Top Companies, New Technology, Demand and Opportunity

The global anti-obesity drugs market is growing significantly, due to high prevalence of obesity and rich pipeline for anti-obesity drugs. The presence of large patient pool and massive unexplored market in the emerging economies, such as India and China, are creating ample opportunities for the growth of the global anti-obesity drugs market. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost-effective anti-obesity drugs, thus driving the growth of the global anti-obesity drugs market.

Obesity can be defined as a medical condition, in which excessive or abnormal accumulation of fat occurs in a patient. A person with body mass index (BMI) of 30 or above is considered obese. There are several factors causing obesity, such as eating habits, physical inactivity, and genetic makeup. Obesity has serious negative impact on an individual’s health. An obese individual is at a higher risk of developing chronic diseases, such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders. According to the WHO, in 2014, there were 600 million obese people aged 18 years or above, which accounted for 13% of the total adult population in the world. The prevalence of obesity is the highest in the U.S. According to the Center for Disease Control and Prevention (CDC), in the U.S., 35.1% of the adult population aged 20 years or above were obese during 2011 - 2012.

Request to Get the Sample Pages at: 

Geographically, North America leads the global anti-obesity drugs market, due to high incidences of obesity, high healthcare expenditure, and increased awareness about obesity and obesity related risks among patients. In addition, the increasing involvement of government and non-government organizations to educate and aware people about the ill effects of obesity, and extensive research and development activities for the development of anti-obesity drugs are fueling the growth of the anti-obesity drugs market in North America. Asia-Pacific is the fastest growing region in the global anti-obesity drugs market. The fastest growth of the region is attributed to improving healthcare infrastructure, growing healthcare expenditure and increasing geriatric population. Moreover, the anti-obesity drugs market is growing due to increasing research and development facilities, growing disposable income, and presence of large patient pool in the emerging countries, such as India and China.

Some of the major players operating in the global anti-obesity drugs market are F. Hoffmann-La Roche AG, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, and Norgine B.V.

Read More..

Read More

Peripheral I.V. Catheter Market Growth Analysis by Manufacturers, Regions, Types, and Applications

The global peripheral I.V. catheter market was valued at $3,702.2 million in 2015, and it is expected to grow at a CAGR of 6.0% during the period 2016 - 2022.

The global market is increasing, due to growing geriatric population and increasing incidence of chronic diseases. In addition, the growing demand for injectable drugs in comparison to the oral medications, increasing healthcare expenditure and technological advancements in peripheral I.V. catheter is encouraging the growth of the global peripheral I.V. catheter market.

Based on type of devices, the integrated/closed peripheral I.V. catheter segment is expected to witness the faster growth during the forecast period. Among the end users, the hospital segment accounted for the largest share in the global market in 2015; and the segment is expected to witness the fastest growth, at 6.5% CAGR during 2016 – 2022.

Request to Get the Sample Pages at https://www.psmarketresearch.com/market-analysis/peripheral-i-v-catheters-market/report-sample

However, the availability of alternative treatments such as oral drug therapies, and injections and complications associated with the usage of peripheral I.V. catheter acts as major restraint in the growth of the global market.  In addition, the high cost of peripheral I.V. catheter is further restraining the growth of the market. The Asia-Pacific market is expected to witness the fastest growth, at a CAGR of 6.8% during the period 2016 – 2022.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=peripheral-i-v-catheters-market

The key companies operating in the global peripheral I.V. catheter market include Becton, Dickinson and Company, Terumo Corporation, B. Braun Melsungen AG, Teleflex Incorporated, Smiths Medical Inc., C.R. Bard Inc., Tangent Medical Technologies Inc., VIGMED AB, Argon Medical Devices Inc., and Medical Components Inc.

Contact:                                            

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Intraoral Scanners Market Comprehensive Review of its Top Companies, Investment trend, Growth Opportunities, Drivers, Technology

Intraoral scanners market is forecasted to attain a size of $442.3 million by 2023.The growth in the intraoral scanners market will be led by increasing prevalence of dental problems, growing geriatric population, and improving accuracy and workflow of intraoral scanners. 

The end users in intraoral scanners market include hospitals and dental clinics. The demand for intraoral scanners in dental clinics is expected to witness fastest growth, at a CAGR of 10.5% during the forecast period, attributable to the increase in number of dental clinics as well as dentists doing private practice, globally.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/intraoral-scanners-market/report-sample

The APAC intraoral scanners industry is expected to witness the fastest growth in demand, at a CAGR of 11.2% during the forecast period, due to higher prevalence of dental problems, and aging population in the region. The growth of the APAC market is supported by rise in healthcare expenditure, strengthening economic condition, and growing pool of dental clinics and practitioners in various APAC countries such as China, Japan, and India. Further, rising awareness among general population about dental problems and the importance of their treatment is another a key factor supporting the market demand in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=intraoral-scanners-market

Globally, key players in the intraoral scanners industry are developing and launching products that are equipped with latest advanced technology and offer various benefits such as enhanced functionality and portability to gain a larger market share. For instance, in March 2017, 3Shape A/S launched the TRIOS 3 Wireless – a wireless version of its TRIOS intraoral scanner. The 3Shape TRIOS 3 Wireless could connect cordlessly to laptops and the TRIOS cart and has three rechargeable batteries.

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication.  Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More